MCRB Seres Therapeutics

Seres Therapeutics to Host Third Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2016 at 8:00 a.m. ET to discuss third quarter 2016 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9944547. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.

A webcast replay with corresponding slides will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ program SER-109 continues to be evaluated in a Phase 2 study in multiply recurrent C. difficile infection. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

EN
04/11/2016

Underlying

MCRBSeres Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seres Therapeutics

 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Participate in Piper Sandler Healthcare Conferen...

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET. A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at and will be available for replay following the event. About Seres Thera...

November 24, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Pr...

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint...

November 5, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Announce Third Quarter 2025 Financial Results an...

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 8471287. To join ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to...

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial product...

October 29, 2025 1 EN
 PRESS RELEASE
Free
MCRB Seres Therapeut...

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b ...

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19–22 in Atlanta, Georgia. Presentation DetailsAbstract ID: 2106936Title: Clinical and...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch